Navigation Links
Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
Date:11/5/2012

SUNNYVALE, Calif., Nov. 5, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for its fiscal 2013 first quarter ended September 30, 2012.

Financial Results for First Quarter Ended September 30, 2012 The GAAP (Generally Accepted Accounting Principles) net income for the fiscal quarter ended September 30, 2012 was $75.6 million, or $1.09 and $1.02 per basic and diluted earnings per share, respectively. This compares with a GAAP net loss of $14.5 million, or $0.21 loss per basic and diluted share for the fiscal quarter ended September 30, 2011.

The non-GAAP net income reported for the fiscal quarter ended September 30, 2012 was $78.8 million, or $1.14 and $1.07 income per basic and diluted earnings per share, respectively. This compares with a non-GAAP net loss of $12.4 million, or $0.18 basic and diluted loss per share, for the fiscal quarter ended September 30, 2011. See "Use of Non-GAAP Financial Measures" below for a description of our Non-GAAP measures. Reconciliation between certain GAAP and non-GAAP measures is provided at the end of this press release.

Revenue for the fiscal quarter ended September 30, 2012 was $102.7 million, compared to $37,000 for the fiscal quarter ended September 30, 2011, an increase of approximately $102.7 million. Revenue for the fiscal quarter ended September 30, 2012 consisted primarily of $100 million of license and milestone revenue due to the Company's achievement of two clinical milestones in connection with the Company's collaboration and license agreement (the "Agreement") with Janssen Biotech, Inc. ("Janssen").

At September 30, 2012, the Company had cash, cash equivalents and marketable securities of $286.1 million, which compares with $203.6 million at June 30, 2012. Total operating expenses excluding share based compensation during the q
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Neurocrine Biosciences Reports Third Quarter 2012 Results
2. PAREXEL International Reports First Quarter Fiscal Year 2013 Results
3. Global Laparotomy Sponge Market 2011-2015: MarketResearchReports.Biz
4. Global Mobile Health Application Market 2011-2015 : MarketResearchReports.Biz
5. Haemonetics Reports Second Quarter Fiscal 2013 Revenue Up 22%, Organic Revenue Up 6% and Adjusted EPS of $0.90, Reaffirms Fiscal 2013 Guidance and Announces Two-For-One Stock Split
6. Anthera Pharmaceuticals Reports 2012 Third Quarter Financial Results And Provides Clinical Progress Update
7. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
8. InspireMD Reports 2012 Fiscal Year Results
9. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
10. Orthobiologics Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018: China Market Research Reports
11. AFCell Medical Reports Results from the Retrospective Study of a Novel Allograft Membrane to Prevent Post-Operative Adhesions in the Repair of Peroneal and Posterior Tibial Tendons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Spartan Bioscience announced today that ... System . It detects CYP2C19 genetic mutations in less ... The Spartan RX CYP2C19 System is the first near-patient ... in Canada. Due to the system’s ease of use, ... by healthcare professionals such as doctors, nurses, pharmacists, and ...
(Date:10/30/2014)... 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... management will present a company overview at the Nomura Biotechnology ... in Boston, MA. A ... "Investors & Media" section of the Company,s website, www.isispharm.com ... within 48 hours and will be archived for a limited ...
(Date:10/30/2014)... that devastated a wide swath of Colorado last year ... and other infrastructure had been upgraded or modernized, according ... Denver. , "People need to understand the importance and ... of structural engineering at the CU Denver College of ... "There is an assumption that a bridge will stand ...
(Date:10/27/2014)... and TORONTO , Oct. ... www.generex.com ) (OTCQB: GNBT) today announced two presentations ... triggered by its novel proprietary cancer immunotherapeutic AE37 ... breast cancer patients. The AE37 cancer vaccine is ... Express, Inc. ( www.antigenexpress.com ). The presentations are ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2CU Denver study says upgrading infrastructure could reduce flood damage 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
... Cell Assurance, Inc. (SCLZ.PK) announced today that it has ... 10 pursuant to Section 12(g) of the Securities Exchange Act ... of December 31, 2009 and 2010 and for the years ... the Company will become an SEC reporting company and will ...
... Healthcare (NYSE: SI ) has appointed Gregory ... Healthcare in the U.S.A., effective June 1.  Sorensen succeeds ... Sorensen will also oversee the Canadian activities of Siemens ... Sorensen will be responsible for leading the marketing, ...
... Rules-Based Medicine, Inc. a leading provider of multiplexed protein ... Pasteur research project Milieu Interieur (the environment ... government.  The project will rely on RBM,s TruCulture®, an ... cellular interactions, to more accurately describe the complexities of ...
Cached Biology Technology:Gregory Sorensen to Head Siemens Healthcare U.S. and Canada Organizations 2Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research 2Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research 3Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research 4
(Date:10/29/2014)... 27, 2014 — Cambridge, MA and Hebei, China — ... complete, high quality sequencing of the Jujube genome. Jujube ... family, and the Jujube genome is particularly difficult to ... complicating factors. It is the first time that a ... This study has been recently published in ...
(Date:10/29/2014)... on a large cohort of kidney cancer patients in ... disease -- and reveals an apparent link between exposure ... in Romania. , The research, by an international team ... Quebec Innovation Centre in Montreal, underscores the importance of ... compound, found in plants of the Aristolochia genus, also ...
(Date:10/28/2014)... Institute of Health (NIH) announced awards to expand ... the National Center for Advancing Translational Sciences (ORDR-NCATS) ... Through the network, physician scientists at 22 consortia ... advance clinical research and investigate new treatments for ... possible by $29 million in fiscal 2014 funding ...
Breaking Biology News(10 mins):BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3
... is available in German . , It is ... fate of individual cells during the early development of organisms. ... of molecular biologists led by Pia Aanstad of the University ... for the interpretation of the concentration of the signaling molecule ...
... Global Crop Diversity Trust announced today numerous new grant ... seed samples maintained in 1,500 crop genebanks around the ... protect food production from the ravages of climate change. ... innovative projects, including a search in Southeast Asia and ...
... experimental vaccine applied the surface of the skin appears ... Scientists from the Research Institute at Nationwide Children,s Hospital ... 109th General Meeting of the American Society for Microbiology ... show that transcutaneous immunization is an effective way to ...
Cached Biology News:Why the thumb of the right hand is on the left hand side 2Hunt for 'climate-ready' crops accelerates as organizations search seed collections worldwide 2Hunt for 'climate-ready' crops accelerates as organizations search seed collections worldwide 3Preventing ear infections in the future: Delivering vaccine through the skin 2
MpV17 transgene, murine homolog, glomerulosclerosis...
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human LT beta R/TNFRSF3 Phycoerythrin MAb (Clone 71319)...
Biology Products: